Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AMTX | PRESS-RELEASE | bearish | 7/10 | Aemetis reported Q2 2026 revenue of $62.7M, up 20% YoY, and operating income of $5.8M versus a $10.7M loss a year ago, d | Aug 6, 2026 |
| ADCT | PRESS-RELEASE | neutral | 1/10 | ADC Therapeutics SA announced it will host a conference call on August 13, 2026 to discuss its Q2 2026 results. | Aug 6, 2026 |
| CMND | PRESS-RELEASE | bullish | 6/10 | Clearmind Medicine received unanimous DSMB approval to advance its Phase I/II trial of CMND-100 for Alcohol Use Disorder | Aug 6, 2026 |
| ANNX | PRESS-RELEASE | bullish | 7/10 | Annexon announced early positive data from the FORWARD open-label study of tanruprubart in Guillain-Barré syndrome (GBS) | Aug 6, 2026 |
| PCRX | PRESS-RELEASE | bullish | 6/10 | Pacira BioSciences reported positive two-year Phase 1 data for PCRX-201, a gene therapy for knee osteoarthritis, publish | Aug 6, 2026 |
| ASND | PRESS-RELEASE | bullish | 7/10 | Ascendis Pharma released positive Phase 2 COACH trial data showing its TransCon CNP + TransCon hGH combination therapy m | Aug 6, 2026 |
| ARGX | PRESS-RELEASE | bullish | 7/10 | argenx has commenced a tender offer to acquire all outstanding shares of Forte Biosciences for $77.00 per share in cash, | Aug 6, 2026 |
| PHVS | PRESS-RELEASE | neutral | 4/10 | Pharvaris announced publication of the first in-depth qualitative study in AAE-C1INH in Frontiers in Immunology, validat | Aug 6, 2026 |
| TARS | PRESS-RELEASE | neutral | 6/10 | Tarsus acquires Alkeus Pharmaceuticals for $450M upfront plus up to $350M in milestones, adding the Phase 3 Stargardt di | Aug 6, 2026 |
| PBH | PRESS-RELEASE | bullish | 6/10 | Prestige Consumer Healthcare reported Q1 FY2027 revenue of $265.7M (+6.5% YoY) and adjusted diluted EPS of $0.98 (+3.2% | Aug 6, 2026 |
| TARS | PRESS-RELEASE | neutral | 1/10 | Tarsus Pharmaceuticals, Inc announced it will report its Q2 2026 results on August 6, 2026. | Aug 5, 2026 |
| ARQT | PRESS-RELEASE | bullish | 7/10 | Arcutis reported Q2 2026 product revenue of $129.9M (+59% YoY) and net income of $15.0M ($0.11 EPS), a significant turna | Aug 5, 2026 |
| BCDA | PRESS-RELEASE | neutral | 1/10 | BioCardia, Inc. announced it will host a conference call on August 12, 2026 to discuss its Q2 2026 results. | Aug 5, 2026 |
| PHGE | PRESS-RELEASE | bearish | 5/10 | BiomX acquired a 10% stake in Motomea for $50,000 cash plus 1.3M restricted shares (pending NYSE approval), gaining acce | Aug 5, 2026 |
| ALT | PRESS-RELEASE | neutral | 1/10 | Altimmune, Inc announced it will report its Q2 2026 results on August 12, 2026. | Aug 5, 2026 |
| KURA | PRESS-RELEASE | neutral | 1/10 | Kura Oncology, Inc. announced it will report its Q2 results on August 12, 2026. | Aug 5, 2026 |
| IMRX | PRESS-RELEASE | neutral | 5/10 | Immuneering reported Q2 2026 net loss of $17.3M ($0.27/share), wider than the $14.4M loss in Q2 2025, driven by increase | Aug 5, 2026 |
| BCTXL | PRESS-RELEASE | bullish | 5/10 | BriaCell received FDA clearance of its Investigational New Drug (IND) application for Bria-PROS+, a next-generation pers | Aug 5, 2026 |
| RXRX | PRESS-RELEASE | mixed | 6/10 | Recursion reported Q2 2026 revenue of $7.7M (well below $12.0M consensus) and a GAAP net loss of -$0.25/share (vs -$0.23 | Aug 5, 2026 |
| ETON | PRESS-RELEASE | bullish | 7/10 | Eton Pharmaceuticals licensed U.S. rights to ASN-001 (timolol topical gel) from Auson Pharmaceuticals, a late-stage rare | Aug 5, 2026 |
| GRCE | PRESS-RELEASE | neutral | 5/10 | Grace Therapeutics announced a ~$10M private placement (4,761,904 shares at $2.10/share) with new and existing fundament | Aug 4, 2026 |
| ATTO | PRESS-RELEASE | neutral | 5/10 | Attovia Therapeutics priced its upsized IPO of 17M shares at $17.00/share, raising $289M in gross proceeds. The company | Aug 4, 2026 |
| RYTM | PRESS-RELEASE | bullish | 7/10 | Rhythm Pharmaceuticals reported Q2 2026 revenue of $71.3M (vs $67.7M consensus, +5.3% beat) and a GAAP EPS loss of -$0.7 | Aug 4, 2026 |
| HRMY | PRESS-RELEASE | bullish | 6/10 | Harmony Biosciences reported Q2 2026 WAKIX net revenue of $261.3M, up 30% YoY and above $253.3M consensus, with diluted | Aug 4, 2026 |
| LPCN | PRESS-RELEASE | neutral | 5/10 | No summary provided | Aug 4, 2026 |
| CRVO | PRESS-RELEASE | bullish | 4/10 | CervoMed announced that neflamapimod, its oral small-molecule candidate for dementia with Lewy bodies (DLB), has been gr | Aug 4, 2026 |
| CRNX | PRESS-RELEASE | bullish | 9/10 | No summary provided | Aug 3, 2026 |
| ORIC | PRESS-RELEASE | neutral | 5/10 | ORIC reported Q2 2026 net loss of $(0.38) per share, missing consensus of $(0.36) by $0.02. The operational highlight is | Aug 3, 2026 |
| CRSP | PRESS-RELEASE | bullish | 6/10 | CRISPR Therapeutics reported Q2 2026 GAAP EPS of -$0.94, beating consensus of -$1.10 by 14.5%, as CASGEVY revenue reache | Aug 3, 2026 |
| KROS | PRESS-RELEASE | neutral | 3/10 | Keros Therapeutics reported Q2 2026 net loss of $28.7M (EPS -$1.45), missing consensus EPS of -$1.24 and zero revenue vs | Aug 3, 2026 |